It's the thought that counts: Craving metacognitions and their role in abstinence from methamphetamine use

Lee, Nicole Kathleen; Pohlman, Sonja; Baker, Amanda; Ferris, Jason; Kay‐Lambkin, Frances

doi:10.1016/j.jsat.2009.12.006

Cited by 25 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, methamphetamine craving has been observed to be present for at least 5 weeks into abstinence, rendering the user particularly vulnerable to relapse during 7 to 14 days of abstinence (Zorick et al, 2010), and is a significant predictor of subsequent use during outpatient treatment (Galloway and Singleton, 2009; Hartz et al, 2001). Craving beliefs, or interpretations and decisions about cravings, have also been shown to predict relapse in a sample of regular methamphetamine users (Lee et al, 2010). On this basis, methamphetamine craving has been advanced as a surrogate marker of methamphetamine dependence (Galloway and Singleton, 2009).…”

Section: Clinical Presentation Of Methamphetamine Use Disordersmentioning

confidence: 99%

Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology, and treatment literature

Courtney

Ray

2014

Drug and Alcohol Dependence

374

255

View full text Add to dashboard Cite

Background-Despite initial reports of a decline in use in the early 2000s, methamphetamine remains a significant public health concern with known neurotoxic and neurocognitive effects to the user. The goal of this review is to update the literature on methamphetamine use and addiction since its assent to peak popularity in 1990s.Methods-Specifically, we first review recent epidemiological reports with a focus on methamphetamine accessibility, changes in use and disorder prevalence rates over time, and accurate estimates of the associated burden of care to the individual and society. Second, we review methamphetamine pharmacology literature with emphasis on the structural and functional neurotoxic effects associated with repeated use of the drug. Third, we briefly outline the findings on methamphetamine-related neurocognitive deficits as assessed via behavioral and neuroimaging paradigms. Lastly, we review the clinical presentation of methamphetamine addiction and the evidence supporting the available psychosocial and pharmacological treatments within the context of an addiction biology framework.Conclusion-Taken together, this review provides a broad-based update of the available literature covering methamphetamine research over the past two decades and concludes with recommendations for future research.

show abstract

Section: Clinical Presentation Of Methamphetamine Use Disordersmentioning

confidence: 99%

Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology, and treatment literature

Courtney

Ray

2014

Drug and Alcohol Dependence

374

255

View full text Add to dashboard Cite

show abstract

“…For example, in cocaine- and MA-dependent individuals, the magnitude of craving and craving-related beliefs are predictive of relapse during treatment (Hartz et al 2001; Rohsenow et al 2007; Paliwal et al 2008; Galloway and Singleton 2009; Lee et al 2010). Further, tonic craving for MA has been observed at least five weeks into abstinence and appears to render users particularly vulnerable to relapse within this period (Hartz et al 2001; Galloway and Singleton 2009; Zorick et al 2010).…”

Section: Introductionmentioning

confidence: 99%

Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder

et al. 2017

View full text Add to dashboard Cite

Rationale Reductions in cue-induced craving and subjective response to drugs of abuse are commonly used as initial outcome measures when testing novel medications for the treatment of addiction. Yet neither the relationship between these two measures at the individual level nor the moderating effects of pharmacotherapies on this relationship has been examined. Objective This secondary data analysis sought to examine 1) the predictive relationship between cue-induced craving and subsequent acute subjective response to methamphetamine (MA) and 2) whether the opioid-receptor antagonist naltrexone moderated this association in a sample of non-treatment-seeking individuals who met DSM-IV criteria for MA use disorder (abuse or dependence). Methods Participants (N = 30) completed two four-day medication regimens (oral naltrexone 50-mg or placebo, in a randomized, counterbalanced, and double-blind fashion). On day four of each medication regimen, participants completed a cue-reactivity paradigm followed by intravenous MA administration. Methamphetamine craving was assessed after the cue-reactivity paradigm, and subjective response to MA was assessed during MA infusion. Results Cue-induced craving for MA was positively associated with post-infusion subjective MA effects, including positive (i.e., stimulation, good effects, feel drug, high), negative (i.e., anxious and depressed), and craving-related (i.e., want more, would like access to drug, crave) responses. Naltrexone, vs. placebo, significantly reduced the association between cue-induced craving and positive subjective response to MA. Conclusions The findings indicate that naltrexone moderates the predictive relationship between cue-induced craving and positive subjective effects of MA, thereby suggesting a behavioral mechanism by which naltrexone may be efficacious in treating MA use disorder.

show abstract

“…Several recent studies of metacognition in addictive behavior (e.g., Lee, Pohlman, Baker, Ferris, & Kay-Lambkin, 2010;Nosen & Woody, 2009;Spada & Wells, 2005) have focused on identifying the specific cognitive and behavioral processes underlying nonacceptance and discomfort with cravings. Positive correlations have been observed between alcohol and drug use and the S-REF metacognitive beliefs developed to explain GAD-style worry (Spada & Wells, 2005;Spada, Zandvoort, & Wells, 2007).…”

mentioning

confidence: 99%

“…Positive correlations have been observed between alcohol and drug use and the S-REF metacognitive beliefs developed to explain GAD-style worry (Spada & Wells, 2005;Spada, Zandvoort, & Wells, 2007). For example, appraisals of cravings as unpleasant (e.g., "This thought disturbs me", "Cravings can drive you crazy") and as uncontrollable and linked to action (e.g., "Once craving starts I have no control over my behavior"; "This thought can really make me drink") correlate positively with craving and depressive symptoms and negatively with cessation self-efficacy in recently abstinent alcohol abusers (Hoyer, Hacker, & Lindenmeyer, 2007) and predict abstinence status among treatment-seeking methamphetamine users (Lee et al, 2010). Similar relationships have been observed between negative, personally significant beliefs about cravings and smoking behavior (Nosen & Woody, 2009;Spada, Nik cevic, Moneta, & Wells, 2007).…”

mentioning

confidence: 99%

Acceptance of cravings: How smoking cessation experiences affect craving beliefs

Nosen

Woody

2014

Behaviour Research and Therapy

View full text Add to dashboard Cite

It's the thought that counts: Craving metacognitions and their role in abstinence from methamphetamine use

Cited by 25 publications

References 16 publications

Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology, and treatment literature

Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology, and treatment literature

Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder

Acceptance of cravings: How smoking cessation experiences affect craving beliefs

Contact Info

Product

Resources

About